Cleerly to Present Innovative Research on Age and Sex-Specific Coronary Artery Disease at AHA Scientific Sessions 2024
New Insights from AI-Quantitative Coronary CT (AI-QCT) Data to be Shared in Chicago, November 16-18, 2024
Cleerly is aware of the lawsuit filed by Heartflow. We are confident in our extensive and well-established intellectual property portfolio and the originality of our technology.
Cleerly has published landmark clinical science that has redefined how cardiovascular disease is understood and treated, which has formed the basis of our novel technologies that provide physicians with actionable insights into their patients’ heart health.
Cleerly was founded on a mission to create a world without heart attacks, and we have never been more focused in our mission and committed to the patients and physicians who count on us.
For any questions, please reach out to press@cleerlyhealth.com
New Insights from AI-Quantitative Coronary CT (AI-QCT) Data to be Shared in Chicago, November 16-18, 2024
Part of the multicenter international CONFIRM2 Registry, the study found key metrics to predict cardiac events
After Five Years of Collaboration, Cleerly’s Innovative Technology Gains Permanent Recognition
The Cleerly-initiated Medicare coverage will begin covering AI-QCT on November 24, 2024